Jacobio-B (01167) has announced that its subsidiary, Beijing Jacobio Pharmaceutical, has received a $100 million initial payment from AstraZeneca PLC. This payment is part of the licensing and collaboration agreement for the pan-KRAS inhibitor JAB-23E73. The receipt of this payment significantly strengthens the group's cash reserves and will support the advancement of its pipeline of innovative oncology therapies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.